Literature DB >> 2831213

Characterization of a camptothecin-resistant human DNA topoisomerase I.

E Kjeldsen1, B J Bonven, T Andoh, K Ishii, K Okada, L Bolund, O Westergaard.   

Abstract

Topoisomerase I purified from a camptothecin-resistant human leukemia cell line and from the parental, camptothecin-sensitive line were compared in vitro. Relaxation of supercoiled DNA by the wild type enzyme was inhibited in the presence of camptothecin, while the mutant enzyme was unimpaired. Camptothecin altered the cleavage pattern of the wild type but not of the mutant enzyme. The stability of cleavable complexes was studied at a preferred topoisomerase I-binding sequence recognized by both enzymes. Camptothecin greatly enhanced the kinetic stability of the cleavable complex formed by the wild type enzyme, whereas that of the mutant enzyme was only marginally affected. In the absence of camptothecin, the cleavable complex formed by the mutant enzyme was stabilized relative to that of the wild type by several criteria. Thus, the mutant enzyme cleaved the topoisomerase I recognition sequence with 2-fold higher efficiency than the wild type enzyme. The mutant cleavable complex had a higher kinetic stability and was less sensitive to salt dissociation than the wild type complex. Furthermore, the mutant enzyme formed cleavable complexes in the absence of divalent cations, which were required for complex formation by the wild type enzyme.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831213

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine.

Authors:  Y Pommier; G S Laco; G Kohlhagen; J M Sayer; H Kroth; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 2.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

Review 3.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 4.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I.

Authors:  I I Gromova; E Kjeldsen; J Q Svejstrup; J Alsner; K Christiansen; O Westergaard
Journal:  Nucleic Acids Res       Date:  1993-02-11       Impact factor: 16.971

Review 6.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5.

Authors:  Eigil Kjeldsen; Christine J F Nielsen; Amit Roy; Cinzia Tesauro; Ann-Katrine Jakobsen; Magnus Stougaard; Birgitta R Knudsen
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

8.  The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I.

Authors:  S E Porter; J J Champoux
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

9.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.

Authors:  H Tamura; C Kohchi; R Yamada; T Ikeda; O Koiwai; E Patterson; J D Keene; K Okada; E Kjeldsen; K Nishikawa
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

10.  Method To Detect Only Live Bacteria during PCR Amplification.

Authors:  Takashi Soejima; Ken-ichiro Iida; Tian Qin; Hiroaki Taniai; Masanori Seki; Shin-ichi Yoshida
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.